Literature DB >> 17161353

Evidence for functional inter-relationships between FOXP3, leukaemia inhibitory factor, and axotrophin/MARCH-7 in transplantation tolerance.

Poorni A D S Muthukumarana1, Gary E Lyons, Yuji Miura, Lorraine H Thompson, Tracy Watson, Colin J Green, Sandra Shurey, Allan D Hess, Bruce R Rosengard, Su M Metcalfe.   

Abstract

In an ex vivo mouse model, regulatory transplantation tolerance is not only linked to Foxp3, but also to release of leukaemia inhibitory factor (LIF) and to expression of axotrophin (also known as MARCH-7), a putative ubiquitin E3 ligase associated with feedback control of T cell activation and of T cell-derived LIF. Given this coordinate correlation with tolerance, we now ask if Foxp3 expression is influenced by LIF or by axotrophin. In spleen cells from allo-rejected mice we found that exogenous LIF reduced interferon gamma release in response to donor antigen by 50%, but LIF had no direct effect on levels of Foxp3 protein in allo-primed cells that were either tolerant, or aggressive, for donor antigen. However, we did find an effect of axotrophin on Foxp3: in the axotrophin null mouse, thymic Foxp3 transcripts were reduced compared to axotrophin wildtype littermates. To test whether these findings in the mouse were of potential significance in man we measured transcript levels of axotrophin and LIF in peripheral blood cell samples collected for a recently published clinical study concerning haematopoietic stem cell recipients. In controls, human peripheral blood CD4+CD25+cells contained significantly more FOXP3 and axotrophin than CD4+CD25-cells. In bone marrow autograft recipients, where peripheral blood cell samples directly represent both the grafted tissue and the immune response, both FOXP3 and axotrophin negatively correlated with graft versus host disease (GVHD). These data suggest that (i) thymic Foxp3+T cell development is influenced by axotrophin; and (ii) clinical auto-GVHD inversely correlates with axotrophin transcript expression as has been previously reported for FOXP3.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17161353     DOI: 10.1016/j.intimp.2006.09.015

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  13 in total

1.  Membrane-associated RING-CH 10 (MARCH10 protein) is a microtubule-associated E3 ubiquitin ligase of the spermatid flagella.

Authors:  Prasanna Vasudevan Iyengar; Tsuyoshi Hirota; Shigehisa Hirose; Nobuhiro Nakamura
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

2.  A LIF/Nanog axis is revealed in T lymphocytes that lack MARCH-7, a RINGv E3 ligase that regulates the LIF-receptor.

Authors:  Lorraine H Thompson; Roy A Whiston; Yerzhan Rakhimov; Cristian Taccioli; Chang-Gong Liu; Carlo Croce; Su M Metcalfe
Journal:  Cell Cycle       Date:  2010-10-04       Impact factor: 4.534

3.  The E3 ligase axotrophin/MARCH-7: protein expression profiling of human tissues reveals links to adult stem cells.

Authors:  Cristina A Szigyarto; Paul Sibbons; Gill Williams; Mathias Uhlen; Su M Metcalfe
Journal:  J Histochem Cytochem       Date:  2009-11-09       Impact factor: 2.479

4.  In primed allo-tolerance, TIM-3-Ig rapidly suppresses TGFbeta, but has no immediate effect on Foxp3.

Authors:  Poorni A D S Muthukumarana; Xin X Zheng; Bruce R Rosengard; Terry B Strom; Susan M Metcalfe
Journal:  Transpl Int       Date:  2008-02-16       Impact factor: 3.782

5.  MARCH7 E3 ubiquitin ligase is highly expressed in developing spermatids of rats and its possible involvement in head and tail formation.

Authors:  Boqiang Zhao; Kunitoshi Ito; Prasanna Vasudevan Iyengar; Shigehisa Hirose; Nobuhiro Nakamura
Journal:  Histochem Cell Biol       Date:  2012-10-27       Impact factor: 4.304

Review 6.  Viral and cellular MARCH ubiquitin ligases and cancer.

Authors:  Xiaoli Wang; Roger A Herr; Ted Hansen
Journal:  Semin Cancer Biol       Date:  2008-10-02       Impact factor: 15.707

7.  Modulation of CD4+ T lymphocyte lineage outcomes with targeted, nanoparticle-mediated cytokine delivery.

Authors:  Jason Park; Wenda Gao; Roy Whiston; Terry B Strom; Su Metcalfe; Tarek M Fahmy
Journal:  Mol Pharm       Date:  2010-12-08       Impact factor: 4.939

8.  Ubiquitin E3 ligase MARCH7 promotes ovarian tumor growth.

Authors:  Jianguo Hu; Ying Meng; Tinghe Yu; Lina Hu; Ming Mao
Journal:  Oncotarget       Date:  2015-05-20

9.  Axotrophin/MARCH7 acts as an E3 ubiquitin ligase and ubiquitinates tau protein in vitro impairing microtubule binding.

Authors:  Katharina Flach; Ellen Ramminger; Isabel Hilbrich; Annika Arsalan-Werner; Franziska Albrecht; Lydia Herrmann; Michel Goedert; Thomas Arendt; Max Holzer
Journal:  Biochim Biophys Acta       Date:  2014-06-04

10.  The ubiquitin E3 ligase MARCH7 is differentially regulated by the deubiquitylating enzymes USP7 and USP9X.

Authors:  James A Nathan; Soma Sengupta; Stephen A Wood; Arie Admon; Gabriel Markson; Chris Sanderson; Paul J Lehner
Journal:  Traffic       Date:  2008-04-11       Impact factor: 6.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.